New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
07:11 EDTACHNAchillion achieves 100% SVR4 in Phase 2 trial of ACH-3102 and sofosbuvir
Achillion Pharmaceuticals announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-na´ve genotype 1 chronic hepatitis C virus infection. Of the 12 patients treated, 100 percent remained HCV RNA undetectable four weeks after completing therapy. Based upon these results, 12 additional patients will begin treatment with six weeks of once daily ACH-3102 and sofosbuvir. "ACH-3102 continues to demonstrate good safety and tolerability through three Phase 2 studies. We believe these studies also confirm a differentiated efficacy profile for an NS5A inhibitor. Achieving 100% SVR4 with eight weeks of treatment with sofosbuvir serving as a nucleotide proxy indicate that dosing 50 mg once daily of ACH-3102 plus a nucleotide inhibitor has the potential to achieve commercially competitive results for curing HCV in a short duration, ribavirin-free doublet," commented David Apelian, EVP and Chief Medical Officer at Achillion. Milind Deshpande, President and CEO of Achillion commented, "As we continue to achieve clinical milestones, we remain focused on execution of the broader clinical development strategy for our HCV portfolio. We expect that Phase 1 proof-of-concept results with ACH-3422 will be reported during the fall of this year, which we anticipate will lead to the start of a Phase 2 combination program to evaluate our proprietary doublet regimen for an eight week, or potentially shorter, treatment regimen for HCV that will begin before the end of 2014."
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
06:09 EDTACHNStocks with implied volatility above IV index mean; RSH ACHN
Stocks with implied volatility above IV index mean; RadioShack (RSH) 278, Achillion (ACHN) 269 according to iVolatility.
December 18, 2014
12:58 EDTACHNAchillion December weekly volatility elevated at 290
Achillion December call option implied volatility is at 205, December weekly at 290, January is at 263; compared to its 26-week average of 156 according to Track Data, suggesting large price movement.
06:00 EDTACHNStocks with implied volatility movement; DO ACHN
Stocks with implied volatility movement; Diamond Offshore (DO) 93, Achillion (ACHN) 285 according to iVolatility.
December 15, 2014
13:06 EDTACHNAchillion December volatility elevated at 285
Achillion December call option implied volatility is at 285, January is at 231; compared to its 26-week average of 153 according to Track Data, suggesting large price movement.
05:58 EDTACHNStocks with implied volatility above IV index mean; ACHN DG
Subscribe for More Information
December 8, 2014
11:49 EDTACHNAchillion December volatility elevated
Subscribe for More Information
08:32 EDTACHNTrout Group to hold events at ASH 2014
Subscribe for More Information
06:12 EDTACHNStocks with implied volatility above IV index mean; LULU ACHN
Stocks with implied volatility above IV index mean; lululemon (LULU) 53, Achillion (ACHN) 216 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use